Document Type
Article
Department
Pathology (East Africa)
Abstract
Background: Multidrug-resistant (MDR) Gram negative rods are increasingly being reported in sub-Saharan Africa. Molecular investigations play an important role, alongside other measures, in controlling nosocomial infections attributed to these organisms.
This study aimed to determine the common extended spectrum beta-lactamases (ESBL) and carbapenemases genes, and clonal relationship in MDR Klebsiella pneumoniae and Escherichia coli.
Methods: Fifty-four MDR isolates collected at the Aga Khan University hospital, Nairobi in the month of August 2012 formed the study. These were picked after an increase in the number of resistant strains during the said period was experienced.
Results: blaCTXM was present in 41 (74%) of the isolates, while blaSHV was detected in 18 (33%) and blaTEM in 13 (24%) of the isolates. Nine (16.7%) of the isolates harboured all three ESBL genes and 8 (14.8%) harboured two. Eight of the isolates (all E. coli) had none of the ESBL genes tested. Two isolates harboured carbapenemases genotypes: one had blaNDM-1 and the other blaSPM.
Sequencing matched CTXM-15 and TEM-1 genes in all the isolates harbouring blaCTXM and blaTEM respectively. However, there was diversity in blaSHV with SHV-11 and SHV-12 genes predominant. The isolates were non-clonal.
Conclusions: The isolates mostly harboured blaCTX-M-15 while only a few had carbapenemases genes. Lack of clonality suggests these were the stable circulating strains at the time of the study.
Publication (Name of Journal)
Microbiologia Medica
Recommended Citation
Maina, D.,
Revathi, G.,
Whitelaw, A. C.
(2017). Molecular characterization of multidrug-resistant Klebsiella pneumoniaeand Escherichia coliharbouring extended spectrum beta-lactamases andcarbapenemases genes at a tertiary hospital, Kenya. Microbiologia Medica, 32(4), 132-137.
Available at:
https://ecommons.aku.edu/eastafrica_fhs_mc_pathol/176
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License